NASDAQ:ALTH - Allos Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started Previous CloseN/AToday's RangeN/A52-Week RangeN/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A Company ProfileFinancialsEarnings HistoryHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Allos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of anti-cancer therapeutics. As of December 31, 2011, the Company focused on the development and commercialization of FOLOTYN (pralatrexate injection). FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. FOLOTYN targets the inhibition of dihydrofolate reductase (DHFR), an enzyme critical in the folate pathway, thereby interfering with deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) synthesis and triggering cancer cell death. FOLOTYN can be delivered as a single agent, for which the Company has approval for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), and can be used in combination therapy regimens. On September 5, 2012, Spectrum Pharmaceuticals, Inc. acquired Allos Therapeutics, Inc. Receive ALTH News and Ratings via Email Sign-up to receive the latest news and ratings for ALTH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A SymbolNASDAQ:ALTH CUSIPN/A Webwww.allos.com Phone+1-303-4266262 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding SharesN/AMarket Cap$0.00 Allos Therapeutics (NASDAQ:ALTH) Frequently Asked Questions What is Allos Therapeutics' stock symbol? Allos Therapeutics trades on the NASDAQ under the ticker symbol "ALTH." What is the consensus analysts' recommendation for Allos Therapeutics? 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allos Therapeutics in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A." Has Allos Therapeutics been receiving favorable news coverage? Press coverage about ALTH stock has trended positive on Sunday, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Allos Therapeutics earned a media sentiment score of 0.28 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 45.74 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future. How do I buy shares of Allos Therapeutics? Shares of ALTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. How can I contact Allos Therapeutics? Allos Therapeutics' mailing address is 11080 Circle Point Rd Ste 200, WESTMINSTER, CO 80020-2778, United States. The biopharmaceutical company can be reached via phone at +1-303-4266262. MarketBeat Community Rating for Allos Therapeutics (NASDAQ ALTH)Community Ranking: 2.0 out of 5 ( )Outperform Votes: 42 (Vote Outperform)Underperform Votes: 63 (Vote Underperform)Total Votes: 105MarketBeat's community ratings are surveys of what our community members think about Allos Therapeutics and other stocks. Vote "Outperform" if you believe ALTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALTH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/15/2018 by MarketBeat.com StaffFeatured Article: Do closed-end mutual funds pay dividends?